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Acute Lymphoblastic Leukemia
Prognostic value of quantitative analysis of WT1
gene transcripts in adult acute lymphoblastic
leukemia
We quantified Wilm’s tumor gene (WT1) using a
real time quantitative polymerase chain reaction in
20 adult patients with acute lymphoblastic
leukemia at presentation. A WT1 level greater than
906 (median value for the whole series) was a sig-
nificant predictor of a poor disease-free and over-
all survival in uni- and multivariate analyses.
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Wilms’ tumor gene (WT1) is a tumor suppressor gene
involved in regulation of cell growth and differentiation.
WT1 transcripts and nuclear protein have been described
in the majority of human acute leukemias.1 The level of
WT1 expression is associated with the presence, persist-
ence or reappearance of leukemic hematopoiesis,2,3 and
has been suggested to represent a potential prognostic
factor. However, while a significant association was
shown between WT1 and prognosis in acute myeloid
leukemia and acute lymphoblastic leukemia (ALL),2,4,5 no
correlation was found in other series.6,7 We analyzed WT1
expression by a real-time quantitative polymerase chain
reaction (RQ-PCR) in 20 adult patients with ALL at diag-
nosis to investigate whether the level of WT1 expression
was associated with clinico-pathologic features and prog-
nosis of the disease. 
All adult patients with newly diagnosed ALL admitted
to the Division of Hematology, S.Giovanni Hospital,
Turin, Italy in 2001 and 2002, were included in the study.
There were 12 females and 8 males; their mean age was
36.6 years (range, 16 to 65). Fifteen had B-ALL and five
had T-ALL. In all, five patients had a normal karyotype,
six had the t(9:22) translocation [Ph positive] and one had
miscellaneous cytogenetic abnormalities. Using a reverse
transcription-polymerase chain reaction (RT-PCR) tech-
nique,8 eight cases showed a BCR/ABL gene rearrange-
ment. All patients were treated according to the multi-
center GIMEMA (Gruppo Italiano Malattie Ematologiche
dell'Adulto) ALL 0496 protocol.9 Follow-up data were ana-
lyzed as of August 31, 2004. 
Total cellular RNA was extracted from bone marrow
mononuclear cells. cDNA was prepared by Reverse tran-
scription following the standardized BIOMED-1 proto-
col.8 RQ-PCR was carried out on the i-Cycler iQ Real PCR
Detection System (BioRad Laboratories, Hercules, CA,
USA) using Taqman fluorescent probes.3 All samples
were processed in triplicate. Serial dilutions of a plasmid
construct containing the sequence targets were used to
obtain a calibration curve for the quantitative assessment
of WT1 and ABL (Figure 1). WT1 values were normalized
to the number of ABL transcripts and expressed as copy
numbers of WT1 for every 104 copies of ABL.
The mean number of WT1 copies/104 ABL copies for
the whole series was 7824 (median, 906; SD, 19786;
range, 3.6 to 86766). A high level of WT1 expression,
defined as >906 copies/104 ABL copies was found in all
five cases of T-ALL but in only five out of the 15 cases of
B-ALL (p=0.01); no association was found with sex, age,
white cell count, cytogenetics or BCR/ABL status.
Seventeen of the 20 patients achieved complete remis-
sion. Using the median WT1 value (906 copies/104 ABL
copies) as a cut-off, the 3-year disease-free survival rates
were 47% for the whole series, 89% for patients with a
WT1 level ≤906 and 0% for those with a higher level
(p=0.01) (Figure 2A). No other parameter was associated
with the duration of disease-free survival. At the time of
analysis nine patients (45%) had died of their disease and
11 (55%) were alive (censored). The mean follow-up for
censored patients was 19.5 months (median, 18.2; range,
3 to 44). Three-year overall survival rates were 42% for
the whole series, 91% for patients with a WT1 level ≤906
and 0% for those with a higher level (p=0.005) (Figure
2B). Overall survival was also shorter for patients with a
white cell count > 50×109/L (p=0.02) and for those with
T-ALL (p=0.04), but was not related to sex, age, cytoge-
netics or BCR/ABL status. At multivariate analysis, WT1
level (χ2, 7; p=0.008; risk ratio, 9.3) and white cell count
(χ2, 3.7; p=0.05; risk ratio, 3.95) retained independent
prognostic significance. 
Figure 1. Representative standard
curves for WT1 (A) and ABL (B)
using real-time quantitative poly-
merase chain reaction analysis.
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Our results indicate that the WT1 gene is expressed in
all cases of adult ALL, contrary to reports showing WT1
expression in only 44 to 86% of ALL.1,10 This result may
depend on the higher sensitivity and specificity of the
RQ-PCR. Indeed, qualitative or semi-quantitative tech-
niques for detecting WT1 transcript do not take into
account the variation resulting from sample handling and
quality of RNA and cDNA, contrary to the double quan-
tification of both WT1 and ABL transcripts.
Secondly, we have clearly demonstrated the high prog-
nostic value of the amount of WT1 expressed in adult
ALL at presentation: patients with high WT1 expression
had shorter disease-free survival and overall survival.
Furthermore, WT1 expression was the most significant
independent prognostic factor in multivariate analysis.
Our results agree with studies showing that high WT1
expression is associated with a poor prognosis in acute
myeloid leukemia and ALL,2,4,5 but contrast with the
results of other studies6,7 that did, however, only investi-
gate cases of acute myeloid leukemia using qualitative or
semi-quantitative RT-PCR assays. To our knowledge, no
study has been performed on a homogeneously treated
series of adult ALL patients using a quantitative
approach. We believe that the level of WT1 expression, as
assessed by RQ-PCR, can be regarded as a risk parameter
in adult ALL.
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Figure 2. Actuarial probability of disease-free survival (A) and over-
all survival (B) for adult patients with acute lymphoblastic
leukemia categorized according to the median WT1 level.
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